The project outcome will enable Industrial enterprises, in particular SMEs and all suppliers to those industries, and Research Institutes working on the development and production of polymeric nanobiomaterials, in particular for drug delivery, to:
- Embrace and sustainably implement Safe by Design thinking in their innovation process;
- Timely identification and management of potential risks, namely for EHS;
- Benefit of the knowledge collected and presented comprehensively;
- Offer a consolidated step-by-step application of SbD for specific polymeric nanobiomaterials
- Reduce uncertainties/increase trust;
- Balance well acceptable costs and risk levels;
- Accelerate innovation outcome and market access for safe nanobiomaterials;
- Successfully capture the opportunities offered by nanobiomaterials, which correspond to an increasing need in the European and international Health systems.